3ddp: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:3ddp.png|left|200px]] | [[Image:3ddp.png|left|200px]] | ||
{{STRUCTURE_3ddp| PDB=3ddp | SCENE= }} | {{STRUCTURE_3ddp| PDB=3ddp | SCENE= }} | ||
===Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8=== | ===Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8=== | ||
{{ABSTRACT_PUBMED_18574471}} | {{ABSTRACT_PUBMED_18574471}} | ||
==About this Structure== | ==About this Structure== | ||
[[3ddp]] is a 4 chain structure of [[Cell Division Protein Kinase 2]] and [[Cyclin]] with sequence from [http://en.wikipedia.org/wiki/Bos_taurus Bos taurus] and [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3DDP OCA]. | |||
==See Also== | |||
*[[Cell Division Protein Kinase 2|Cell Division Protein Kinase 2]] | |||
*[[Cyclin|Cyclin]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:018574471</ref><references group="xtra"/> | ||
[[Category: Bos taurus]] | [[Category: Bos taurus]] | ||
[[Category: Cyclin-dependent kinase]] | [[Category: Cyclin-dependent kinase]] | ||
| Line 33: | Line 25: | ||
[[Category: Cell division]] | [[Category: Cell division]] | ||
[[Category: Cyclin]] | [[Category: Cyclin]] | ||
[[Category: Mitosis]] | [[Category: Mitosis]] | ||
[[Category: Nucleotide-binding]] | [[Category: Nucleotide-binding]] | ||
| Line 39: | Line 30: | ||
[[Category: Phosphoprotein]] | [[Category: Phosphoprotein]] | ||
[[Category: Phosphorylation]] | [[Category: Phosphorylation]] | ||
[[Category: Ser/thr protein kinase]] | [[Category: Ser/thr protein kinase]] | ||
[[Category: Serine/threonine-protein kinase]] | [[Category: Serine/threonine-protein kinase]] | ||
[[Category: Transferase | [[Category: Transferase-cell cycle complex]] | ||
Revision as of 13:33, 26 July 2012
Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8Structure of phosphorylated Thr160 CDK2/cyclin A in complex with the inhibitor CR8
Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against non-small-cell lung and nasopharyngeal cancers. An extensive medicinal chemistry study, designed to generate more potent analogues of roscovitine, led to the identification of an optimal substitution at the N6 position (compound CR8). An extensive selectivity study (108 kinases) highlights the exquisite selectivity of CR8 for CDK1/2/3/5/7/9. CR8 was 2- to 4-fold more potent than (R)-roscovitine at inhibiting these kinases. Cocrystal structures of (R)-CR8 and (R)-roscovitine with pCDK2/cyclin A showed that both inhibitors adopt essentially identical positions. The cellular effects of CR8 and (R)-roscovitine were investigated in human neuroblastoma SH-SY5Y cells. CR8 inhibited the phosphorylation of CDK1 and 9 substrates, with a 25-50 times higher potency compared to (R)-roscovitine. CR8 was consistently more potent than (R)-roscovitine at inducing apoptotic cell death parameters: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 2H-tetrazolium reduction (40-fold), lactate dehydrogenase release (35-fold), caspases activation (68-fold) and poly-(ADP-ribose)polymerase cleavage (50-fold). This improved cell death-inducing activity of CR8 over (R)-roscovitine was observed in 25 different cell lines. Altogether these results show that second-generation analogues of (R)-roscovitine can be designed with improved antitumor potential.
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases., Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L, Oncogene. 2008 Oct 2;27(44):5797-807. Epub 2008 Jun 23. PMID:18574471
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
About this StructureAbout this Structure
3ddp is a 4 chain structure of Cell Division Protein Kinase 2 and Cyclin with sequence from Bos taurus and Homo sapiens. Full crystallographic information is available from OCA.
See AlsoSee Also
ReferenceReference
- ↑ Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807. Epub 2008 Jun 23. PMID:18574471 doi:10.1038/onc.2008.191